The Latest Headlines at American Banking and Market News
Q4 2024 EPS Estimates for SurgePays, Inc. (NASDAQ:SURG) Cut by Sidoti Csr
SurgePays, Inc. (NASDAQ:SURG – Free Report) – Equities research analysts at Sidoti Csr cut their Q4 2024 EPS estimates for shares of SurgePays in a report released on Tuesday, May 14th. Sidoti Csr analyst A. Soderstrom... More of this article »
PCCW (OTCMKTS:PCWLF) Trading Down 1.9%
PCCW Limited (OTCMKTS:PCWLF – Get Free Report)’s share price traded down 1.9% on Wednesday . The company traded as low as $0.51 and last traded at $0.53. 950 shares changed hands during trading, a decline of 81% from the... More of this article »
Cormark Comments on Chesswood Group Limited’s Q4 2024 Earnings (TSE:CHW)
Chesswood Group Limited (TSE:CHW – Free Report) – Investment analysts at Cormark cut their Q4 2024 EPS estimates for shares of Chesswood Group in a report issued on Monday, May 13th. Cormark analyst J. Fenwick now anticipates... More of this article »
D-Wave Quantum (NYSE:QBTS) Stock Rating Reaffirmed by Needham & Company LLC
D-Wave Quantum (NYSE:QBTS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued on Tuesday, Benzinga reports. They presently have... More of this article »
Roblox’s (RBLX) “Neutral” Rating Reiterated at Roth Mkm
Roblox (NYSE:RBLX – Get Free Report)‘s stock had its “neutral” rating reaffirmed by Roth Mkm in a research report issued on Tuesday, Benzinga reports. They currently have a $35.00 price objective on the stock,... More of this article »
Tenable (NASDAQ:TENB) Stock Rating Reaffirmed by Needham & Company LLC
Tenable (NASDAQ:TENB – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a report issued on Tuesday, Benzinga reports. They currently have a $62.00... More of this article »
Oppenheimer Trims Fulcrum Therapeutics (NASDAQ:FULC) Target Price to $14.00
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) had its price target reduced by research analysts at Oppenheimer from $16.00 to $14.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has an... More of this article »
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Outperform Rating from Analysts at Evercore ISI
Equities researchers at Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) in a research note issued on Tuesday, Benzinga reports. The brokerage set an “outperform”... More of this article »
Crinetics Pharmaceuticals’ (CRNX) “Overweight” Rating Reaffirmed at Cantor Fitzgerald
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a research note issued on Tuesday, Benzinga reports. They... More of this article »
Beyond’s (BYON) Outperform Rating Reaffirmed at Wedbush
Beyond (NYSE:BYON – Get Free Report)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a report released on Tuesday, Benzinga reports. They presently have a $37.00 price target... More of this article »
BJ’s Wholesale Club (NYSE:BJ) Price Target Raised to $78.00
BJ’s Wholesale Club (NYSE:BJ – Get Free Report) had its target price hoisted by Evercore ISI from $76.00 to $78.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “in-line”... More of this article »
Moderna (NASDAQ:MRNA) Coverage Initiated by Analysts at Evercore ISI
Equities researchers at Evercore ISI began coverage on shares of Moderna (NASDAQ:MRNA – Get Free Report) in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm set an “in-line”... More of this article »
Sarepta Therapeutics (NASDAQ:SRPT) Lifted to Outperform at Oppenheimer
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by Oppenheimer from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, MarketBeat reports.... More of this article »